182 related articles for article (PubMed ID: 24778390)
1. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
[No Abstract] [Full Text] [Related]
2. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
3. Successful management of life-threatening disseminated intravascular coagulopathy due to metastatic melanoma.
Bhattacharyya A; Cooper A; Hong A; Iland H; McNeil C
Intern Med J; 2014 Feb; 44(2):207-8. PubMed ID: 24528820
[No Abstract] [Full Text] [Related]
4. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
5. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
6. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
Mesko SM; Rosenthal KJ; Boasberg PD; Hamid O
J Clin Oncol; 2015 Sep; 33(25):e101-3. PubMed ID: 24711550
[No Abstract] [Full Text] [Related]
7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
8. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
9. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
[No Abstract] [Full Text] [Related]
10. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
Sibaud V; Chevreau C
Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
[No Abstract] [Full Text] [Related]
11. [Treatment of metastatic melanoma with BRAF inhibitors].
Hafner C
Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
[No Abstract] [Full Text] [Related]
12. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
14. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
15. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
16. [BRAF mutation detection in metastatic melanoma].
Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
[No Abstract] [Full Text] [Related]
17. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
18. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
19. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
Kaplan FM; Mastrangelo MJ; Aplin AE
J Invest Dermatol; 2010 Nov; 130(11):2669-71. PubMed ID: 20574441
[No Abstract] [Full Text] [Related]
20. Melanoma brain metastases and vemurafenib: need for further investigation.
Rochet NM; Dronca RS; Kottschade LA; Chavan RN; Gorman B; Gilbertson JR; Markovic SN
Mayo Clin Proc; 2012 Oct; 87(10):976-81. PubMed ID: 23036672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
